Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001–2016)

[1]  L. Pusztai,et al.  Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy. , 2018, The oncologist.

[2]  Christine Y. Lu,et al.  Trastuzumab for metastatic breast cancer: Real world outcomes from an Australian whole-of-population cohort (2001-2016). , 2018, Breast.

[3]  Christine Y. Lu,et al.  Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006–2014) , 2017, British Journal of Cancer.

[4]  S. Rodenhuis,et al.  Abstract P4-21-30: Long-term survival in HER2-positive metastatic breast cancer: The first blow is half the battle , 2017 .

[5]  A. Tutt,et al.  3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Christine Y. Lu,et al.  Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort , 2017, BMJ Open.

[7]  A. Tutt,et al.  3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). , 2017, Breast.

[8]  G. Hortobagyi,et al.  Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer , 2016, Breast Cancer Research and Treatment.

[9]  W. Lipworth,et al.  Access to new cancer medicines in Australia: dispelling the myths and informing a public debate , 2016, Journal of Pharmaceutical Policy and Practice.

[10]  S. Merajver,et al.  Clinical predictors of long-term survival in HER2-positive metastatic breast cancer , 2016, Breast Cancer Research and Treatment.

[11]  I. Smith,et al.  Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab. , 2015, Breast.

[12]  F. André,et al.  Long term HER2+ metastatic breast cancer survivors treated by trastuzumab: Results from the French cohort study LHORA. , 2015, Breast.

[13]  Martin Schumacher,et al.  Conditional Survival: A Useful Concept to Provide Information on How Prognosis Evolves over Time , 2015, Clinical Cancer Research.

[14]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.

[15]  E. Espinosa,et al.  The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+ Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy , 2014, PloS one.

[16]  M. Stockler,et al.  Rising cost of anticancer drugs in Australia , 2014, Internal medicine journal.

[17]  H. Rugo,et al.  Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER , 2014, British Journal of Cancer.

[18]  F. Jänicke,et al.  Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry , 2014, BMC Cancer.

[19]  Erin M. Olson,et al.  Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. , 2013, Clinical breast cancer.

[20]  F. Claret,et al.  Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer , 2012, Front. Oncol..

[21]  G. Hortobagyi,et al.  Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Ward,et al.  Trastuzumab and metastatic breast cancer: trastuzumab use in Australia--monitoring the effect of an expensive medicine access program. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.